{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:32:51Z","timestamp":1793201571624,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1001\/jamaneurol.2018.0024","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T12:31:46Z","timestamp":1520253106000},"page":"690","source":"Crossref","is-referenced-by-count":112,"title":["Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids"],"prefix":"10.1001","volume":"75","author":[{"given":"Sarah A.","family":"Morrow","sequence":"first","affiliation":[{"name":"Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada"},{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alexander","family":"Fraser","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada"},{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada"},{"name":"Department of Ophthalmology, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Day","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bowman","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Rosehart","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Kremenchutzky","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada"},{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nicolle","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada"},{"name":"Department of Clinical Neurological Sciences, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"noi180001r1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1001\/archopht.1972.01000020137004","article-title":"Optic neuritis and multiple sclerosis: an epidemiologic study.","volume":"87","author":"Percy","year":"1972","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"noi180001r2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis.","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"noi180001r3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/01.WNL.0000138572.82125.F5","article-title":"The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.","volume":"63","author":"Morrow","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"noi180001r4","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1212\/WNL.50.6.1833","article-title":"Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study.","volume":"50","author":"Oliveri","year":"1998","journal-title":"Neurology"},{"issue":"22","key":"noi180001r5","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1212\/WNL.0b013e3181c3fd5b","article-title":"A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.","volume":"73","author":"Martinelli","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"noi180001r6","first-page":"CD006921","article-title":"Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.","author":"Burton","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"9997","key":"noi180001r7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"noi180001r8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9394(00)00740-6","article-title":"Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis: report of the quality standards subcommittee of the American Academy of Neurology.","volume":"130","author":"Kaufman","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"noi180001r9","first-page":"CD001430","article-title":"Corticosteroids for treating optic neuritis.","author":"Gal","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"noi180001r10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/B978-0-444-52001-2.00020-0","article-title":"Glucocorticoid treatment of multiple sclerosis.","volume":"122","author":"Goodin","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"noi180001r11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/ICU.0000000000000197","article-title":"Should patients with optic neuritis be treated with steroids?","volume":"26","author":"Mackay","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"noi180001r12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.optom.2013.12.008","article-title":"Optic neuritis in pediatric population: a review in current tendencies of diagnosis and management.","volume":"7","author":"P\u00e9rez-Cambrod\u00ed","year":"2014","journal-title":"J Optom"},{"issue":"2","key":"noi180001r13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1017\/S0317167100120293","article-title":"High dose oral steroids commonly used to treat relapses in Canadian MS clinics.","volume":"36","author":"Morrow","year":"2009","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"noi180001r14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1017\/S0317167100013500","article-title":"MS patients report excellent compliance with oral prednisone for acute relapses.","volume":"39","author":"Morrow","year":"2012","journal-title":"Can J Neurol Sci"},{"issue":"7","key":"noi180001r15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/ene.2008.15.issue-7","article-title":"Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.","volume":"15","author":"Perumal","year":"2008","journal-title":"Eur J Neurol"},{"issue":"1","key":"noi180001r16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/WNL.0b013e3181aaea32","article-title":"Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis.","volume":"73","author":"Naismith","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"noi180001r17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF01203696","article-title":"The effect of oral prednisolone on visual evoked potential latencies in acute optic neuritis monitored in a prospective, randomized, controlled study.","volume":"91","author":"Trauzettel-Klosinski","year":"1995-1996","journal-title":"Doc Ophthalmol"},{"issue":"pt 6","key":"noi180001r18","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/brain\/114.6.2437","article-title":"The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits.","volume":"114","author":"Youl","year":"1991","journal-title":"Brain"},{"issue":"11","key":"noi180001r19","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","article-title":"The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial.","volume":"101","author":"Beck","year":"1994","journal-title":"Ophthalmology"},{"issue":"3","key":"noi180001r20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0303-8467(92)90088-K","article-title":"Evaluation of the visual system in multiple sclerosis: a comparative study of diagnostic tests.","volume":"94","author":"van Diemen","year":"1992","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"noi180001r21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10633-009-9195-4","article-title":"ISCEV standard for clinical visual evoked potentials (2009 update).","volume":"120","author":"Odom","year":"2010","journal-title":"Doc Ophthalmol"},{"issue":"2","key":"noi180001r22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00004691-200604000-00006","article-title":"Guideline 5: guidelines for standard electrode position nomenclature.","volume":"23","author":"American Clinical Neurophysiology Society","year":"2006","journal-title":"J Clin Neurophysiol"},{"key":"noi180001r23","first-page":"311","article-title":"Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (An AOS Thesis).","volume":"107","author":"Kaiser","year":"2009","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"noi180001r24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0161-6420(96)30742-2","article-title":"Standardizing the measurement of visual acuity for clinical research studies: guidelines from the Eye Care Technology Forum.","volume":"103","author":"Ferris","year":"1996","journal-title":"Ophthalmology"},{"issue":"10","key":"noi180001r25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1212\/01.WNL.0000094315.19931.90","article-title":"Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.","volume":"61","author":"Balcer","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"noi180001r26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/135245850000600305","article-title":"New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis.","volume":"6","author":"Balcer","year":"2000","journal-title":"Mult Scler"},{"key":"noi180001r27","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1212\/WNL.0b013e3181dbb664","article-title":"Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity.","volume":"74","author":"Balcer","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"noi180001r28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1212\/WNL.59.5.679","article-title":"Benefit of interferon \u00df-1a on MSFC progression in secondary progressive MS.","volume":"59","author":"Cohen","year":"2002","journal-title":"Neurology"},{"issue":"16","key":"noi180001r29","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1212\/01.wnl.0000259521.14704.a8","article-title":"Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.","volume":"68","author":"Balcer","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"noi180001r30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp.50.7.840","article-title":"The rapid assessment of visual dysfunction in multiple sclerosis.","volume":"50","author":"Della Sala","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"noi180001r31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jnnp.40.10.1009","article-title":"Pattern reversal evoked visual potential in the diagnosis of multiple sclerosis.","volume":"40","author":"Matthews","year":"1977","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"noi180001r32","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1167\/iovs.03-1213","article-title":"Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity.","volume":"46","author":"Sisto","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"noi180001r33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1474-4422(05)00992-0","article-title":"The neuro-ophthalmology of multiple sclerosis.","volume":"4","author":"Frohman","year":"2005","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi180001r34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00055735-200212000-00006","article-title":"Acute demyelinating optic neuritis.","volume":"13","author":"Foroozan","year":"2002","journal-title":"Curr Opin Ophthalmol"},{"issue":"7","key":"noi180001r35","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1212\/WNL.52.7.1479","article-title":"A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis.","volume":"52","author":"Sellebjerg","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"noi180001r36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00415-009-0123-z","article-title":"Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis.","volume":"256","author":"Kolappan","year":"2009","journal-title":"J Neurol"},{"issue":"6","key":"noi180001r37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jnnp.55.6.450","article-title":"High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect.","volume":"55","author":"Miller","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"noi180001r38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1017\/S0317167100034053","article-title":"Cost analysis of methylprednisolone treatment of multiple sclerosis patients.","volume":"25","author":"Robson","year":"1998","journal-title":"Can J Neurol Sci"},{"issue":"15","key":"noi180001r39","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1212\/WNL.0000000000003113","article-title":"Reducing costs while enhancing quality of care in MS.","volume":"87","author":"Kister","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"noi180001r40","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0000000000000013","article-title":"Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology.","volume":"82","author":"Minden","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"noi180001r41","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1474-4422(06)70450-1","article-title":"Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial.","volume":"5","author":"Chataway","year":"2006","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi180001r44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ana.22005","article-title":"Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis.","volume":"67","author":"Talman","year":"2010","journal-title":"Ann Neurol"},{"issue":"7","key":"noi180001r45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/jphp.1979.31.issue-1","article-title":"Relative bioavailability of prednisone and prednisolone in man.","volume":"31","author":"Tse","year":"1979","journal-title":"J Pharm Pharmacol"},{"key":"noi180001r43","article-title":"Multiple sclerosis relapses: budget impact analysis of oral high-dose corticosteroids","author":"Veillard","year":"2017"},{"key":"noi180001r42","unstructured":"Multiple sclerosis: management of multiple sclerosis in primary and secondary care: clinical guideline 186. National Clinical Guideline Centre. https:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0068954\/pdf\/PubMedHealth_PMH0068954.pdf. Published 2014. Accessed October 26, 2017."},{"key":"noi180001r46","unstructured":"International Journal of MS Care. Abstracts From the 19th annual meeting of the Consortium of Multiple Sclerosis Centers. Summer 2005;7(2):45-76. http:\/\/ijmsc.org\/doi\/abs\/10.7224\/1537-2073-7.2.45?code=cmsc-site. Accessed October 26, 2017."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2673723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T15:15:16Z","timestamp":1719846916000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2018.0024"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2018.0024","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732806595.793546357","asserted-by":"object"}]},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}